Canada markets closed

Exactus, Inc. (EXDI)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0700-0.0075 (-9.68%)
At close: 1:32PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0775
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0700 - 0.0700
52 Week Range0.0400 - 0.2670
Avg. Volume36,411
Market Cap7.83M
Beta (5Y Monthly)4.32
PE Ratio (TTM)N/A
EPS (TTM)-0.2310
Earnings DateJul. 01, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A

    Exactus, Inc. Reports Third Quarter 2020 Financial Results

    Third Quarter 2020 Highlights * Total Net Revenue of $678,050 * Achieved Gross Profit of $114,529 * Continuation of Sales & Marketing Buildout * Alibaba Storefront LaunchDELRAY BEACH, FL / ACCESSWIRE / November 19, 2020 / Exactus, Inc.

  • GlobeNewswire

    Exactus, Inc. Reports Second Quarter 2020 Financial Results and Conference Call

    Second Quarter 2020 Highlights * Total Net Revenue of $531,240 * Continuation of Sales & Marketing Buildout * White Label Division Launch * European Sales Expansion * Strengthened the Balance SheetDELRAY BEACH, Fla., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Exactus, Inc. (OTCQB: EXDI) (the “Company”) a leading supplier of hemp-derived ingredients (CBD/CBG) and feminized hemp genetics, reported its financial results for the second quarter 2020 and conference call dial-in information.During the second quarter of 2020, Exactus continued to generate year over year revenue growth through a time of pandemic.Focusing on core competencies of bulk raw ingredients, the company has built a solid pipeline of potential opportunities and has been successful in selling into the European market.The company has continued to attract top talent with the additions Daniel Alberttis as Chief Operating Officer, Mark Alouf as Director of Sales, and recruited Sonya Bain as Sales Manager and Product Specialist to facilitate the growth and manage large scale accounts.With these additions, the Company will be directing its efforts to specialty ingredients, and white label business to expand its customer base and leverage its relationships to drive more profitable and scalable revenue.Emiliano Aloi, Interim CEO of Exactus stated, "We are happy to see that our strategic shift is bringing fundamental and tangible results. Our board and management team have worked closely and diligently to achieve this transition. We feel that we are coming together as a company and bringing forth the solutions that our clients and shareholders want. Our year over year sales are up, our burn is down, and our debt is shrinking. Specifically, we are very proud of our new integrated CRM, sales, and E-commerce integration that Mark Alouf and his team have put together, and of Sonya Bain’s leadership in launching our white label division. These are the results that we need to strengthen our position in the market and to enable Exactus to engage in its M&A growth strategy.”Second Quarter 2020 Financial SummaryTotal net revenue for the second quarter 2020 was $531,240 versus $139,683 in the prior year. The increase in revenue was primarily attributable to the build out of sales and marketing. Net loss for the quarter was -$1,529,070 versus -$955,226 million in the prior year. The net loss for the second quarter 2020 was due, primarily, to non-cash expenses for stock-based compensation.Conference CallManagement will hold a conference call on Thursday, August 20, 2020 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its second quarter 2020 results and its business outlook. To access this call, dial 1-877-451-6152 (domestic) or 1-201-389-0879 (international).  The conference ID is 13708862.Following the conference call, a replay will be available at 1-844-512-2921 (domestic) or 1-412-317-6671 (international). The replay passcode is 13708862.The conference call will be broadcast and available for replay on the investor relations section of the Exactus’ website and at learn more about Exactus, Inc., visit the website at Exactus:  Exactus Inc. (OTCQB:EXDI) is a leading producer and supplier of hemp-derived ingredients and feminized hemp genetics. Exactus is committed to creating a positive impact on society and the environment promoting sustainable agricultural practices. Exactus specializes in hemp-derived ingredients (CBD/CBG/CBC/CBN) and feminized seeds that meet the highest standards of quality and traceability. Through research and development, the Company continues to stay ahead of market trends and regulations.  Exactus is at the forefront of product development for the beverage, food, pets, cosmetics, wellness, and pharmaceutical industries.For more information about Exactus: Notice: Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks, uncertainties and forward-looking statements described under "Risk Factors" in Item 1A of our most recent Form 10-K for the fiscal year ended December 31, 2019 filed with the Securities and Exchange Commission (the "SEC") on May 22, 2020, and in other periodic and current reports we file with the SEC. If any of these risks were to occur, our business, financial condition, or results of operations would likely suffer. In that event, the value of our securities could decline, and you could lose part or all of your investment. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. In addition, our past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results in the future. See "Safe Harbor" below.Safe Harbor - Forward-Looking Statements: The information provided in this press release may include forward-looking statements relating to future events or the future financial performance of Exactus, including statements concerning harvest expectations, the impact of Exactus’ acquisition of Green Goddess, LeVor Collection, and interests in the 2019 harvest on its supply and product line expansion, Exactus’ ability to monetize its harvest, Exactus’ ability to expand its product lines and brands, the amount of future orders for Exactus products, and Exactus’ future revenue, gross margins and working capital. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of Exactus and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to Exactus may be found in Exactus’ periodic and current filings with the SEC, including the factors described in the sections entitled "Risk Factors", copies of which may be obtained from the SEC's website at Any forward-looking statement speaks only as of the date on which such statement is made, and Exactus does not intend to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise.Exactus Contact:Andrew Johnson Chief Strategy Officer Exactus Inc. 509-999-9695        Condensed Balance Sheets (Unaudited) - USD ($)Jun. 30, 2020Dec. 31, 2019 Current Assets:    Cash and cash equivalents $298,754  $18,405  Accounts receivable, net  42,895   55,725  Accounts receivable - related party  107,660   18,860  Inventory  340,528   1,337,809  Prepaid expenses and other current assets - current  60,114   248,776  Prepaid expenses and other current assets - related party - current  622,159   622,160  Due from related parties  0   127,500  Total current assets  1,472,110   2,429,235  Other Assets:    Deposits  0   80,000  Prepaid expenses and other current assets - long term  9,589   0  Prepaid expenses and other current assets - related party - long-term  2,175,000   2,492,045  Property and equipment, net  405,775   477,433  Intangible assets, net  1,656,894   2,147,311  Operating lease right-of-use assets, net  310,694   390,810  Total other assets  4,557,952   5,587,599  TOTAL ASSETS  6,030,062   8,016,834  Current Liabilities:    Accounts payable  2,026,841   1,442,409  Accounts payable - related party  454,511   454,511  Accrued expenses  589,148   238,010  Unearned revenue -related party  0   215,000  Notes payable - current portion  90,755   0  Note payable - related parties  78,017   55,556  Subscription payable  250,000   250,000  Convertible notes, net of discounts  575,979   85,906  Derivative liability  468,387   880,410  Interest payable  39,332   16,677  Due to related party  84,500   0  Operating lease liabilities, current portion  178,541   169,869  Total current liabilities  4,836,011   3,808,348  Long Term Liabilities:    Convertible notes payable  0   100,000  Notes payable - long-term portion  244,755   0  Operating lease liabilities, long-term portion  132,154   220,942  Total long term liabilities  376,909   320,942  TOTAL LIABILITIES  5,212,920   4,129,290       Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)3 Months Ended6 Months Ended Jun. 30, 2020Jun. 30, 2019Jun. 30, 2020Jun. 30, 2019 Income Statement     Net revenues$531,240  $99,164  $1,051,440  $115,144  Net revenues - related party 0   40,519   315,800   40,519  Net revenues 531,240   139,683   1,367,240   155,663  Cost of sales 562,270   0   1,604,743   0  Cost of sales - related party 60,000   103,187   417,783   115,787  Total cost of sales 622,270   103,187   2,022,526   115,787  Gross profit (loss) (91,030)  36,496   (655,286)  39,876  Operating Expenses:     General and administration 760,306   622,079   1,820,893   1,274,288  Selling and marketing expenses 132,110   176,602   413,000   228,480  Professional and consulting 552,197   330,891   1,280,068   2,211,038  Research and development 0   11,975   0   26,975  Total operating expenses 1,444,613   1,141,547   3,513,961   3,740,781  Loss from Operations (1,535,643)  (1,105,051)  (4,169,247)  (3,700,905) Other Income (Expenses):     Derivative gain (loss) 249,982   0   356,468   (1,454,729) Gain on extinguishment of debt, net 39,142   0   39,142   0  (Loss) gain on settlement of debt, net (16,500)  0   (23,000)  3,007,629  Interest expense (420,675)  (2,519)  (709,141)  (369,432) Total Other Income (Expenses), net (148,051)  (2,519)  (336,531)  1,183,468  Loss Before Provision for Income Taxes (1,683,694)  (1,107,570)  (4,505,778)  (2,517,437) Provision for income tax 0   0   0   0  Net Loss (1,683,694)  (1,107,570)  (4,505,778)  (2,517,437) Net Loss attributable to non-controlling interest 154,624   152,344   310,443   187,948  Net Loss Attributable to Exactus, Inc. (1,529,070)  (955,226)  (4,195,335)  (2,329,489) Deemed dividend on Preferred Stock 0   0   0   (904,450) Net Loss available to Exactus, Inc. common stockholders$(1,529,070) $(955,226) $(4,195,335) $(3,233,939) Net Loss per Common Share - Basic and Diluted$(0.03) $(0.03) $(0.10) $(0.09) Net Loss attributable to non-controlling interest per Common Share - Basic and Diluted 0   0   (0.01)  (0.01) Net Loss available to Exactus, Inc. common stockholders per Common Share - Basic and Diluted$(0.03) $(0.03) $(0.09) $(0.12) Weighted Average Number of Common Shares Outstanding: Basic and Diluted 48,203,183   35,203,356   46,757,076   27,227,822                   Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)6 Months Ended Jun. 30, 2020Jun. 30, 2019 Cash Flows From Operating Activities:   Net loss$(4,505,778) $(2,517,437) Adjustments to reconcile net loss to cash used in operations:   Depreciation 53,787   11,851  Derivative (gain) loss (356,468)  1,454,729  Gain on extinguishment of debt, net (39,142)  0  Stock-based compensation 1,023,303   2,083,638  Bad debt expense 51,470   0  Impairment expense 57,871   0  Inventory reserve 660,000   0  Amortization of prepaid stock-based expenses 378,138   0  Amortization of discount and debt issuance costs for convertible notes 579,115   339,806  Amortization of intangible assets 490,417   299,355  Amortization of operating lease right-of-use assets 80,116   0  Non-cash interest expense 90,000   0  Loss (gain) on settlement of debt 23,000   (3,007,629) (Increase) decrease in operating assets:   Accounts receivable (38,640)  (69,914) Accounts receivable - related party (88,800)  (40,519) Inventory 337,281   (1,047,781) Advance to supplier - related party 0   (820,108) Prepaid expenses and other current assets - current 127,570   (289,227) Prepaid expenses and other current assets - long term (9,589)  0  Deposit 40,000   0  Increase (decrease) in operating liabilities:   Accounts payable 561,432   105,400  Accounts payable - related party 0   6,762  Accrued expenses 351,138   0  Unearned revenues (215,000)  0  Interest payable 28,815   6,746  Operating lease liabilities (80,116)  0  Net Cash Used In Operating Activities (400,080)  (3,484,328) Cash Flows From Investing Activities:   Purchase of membership interest in subsidiary 0   (1,000,000) Purchase of property and equipment 0   (385,382) Net Cash Used In Investing Activities 0   (1,385,382) Cash Flows From Financing Activities:   Advances from related party 97,000   30,000  Repayments on related party advances (12,500)  0  Proceeds from sale of Common Stock 350,000   5,478,838  Payments of principal on notes payable 0   (11,129) Proceeds from issuance of notes payable 355,929   14,229  Payments of principal on convertible notes (110,000)  (186,443) Proceeds from issuance of convertible notes, net of issuance cost 0   206,900  Net Cash Provided By Financing Activities 680,429   5,532,395  Net increase in cash and cash equivalents 280,349   662,685  Cash and cash equivalents at beginning of period 18,405   1,960  Cash and cash equivalents at end of period 298,754   664,645  Supplemental Cash Flow Information:   Cash paid for interest and finance charges 11,211   22,890  Cash paid for taxes 0   0  Non-Cash transactions investing and financing activity:   Proceeds from sale of Series A preferred stock paid directly to settle debts 0   55,090  Convertible notes and interest payable settled by Series A preferred stock issued 0   849,360  Note payable, accrued expense and interest payable settled by common stock issued 83,160   40,616  Convertible notes settled by common stock issued 0   196,000  Common stock issued for purchase of membership interest in subsidiary 0   1,440,000  Increase in intangible assets for subscription payable 0   1,650,000  Initial beneficial conversion feature and debt discount on convertible notes 0   206,910  Preferred deemed dividend 0   904,450  Operating lease right-of-use assets and operating lease liabilities recorded upon adoption of ASC 842 0   506,506  Reduction of operating lease right-of-use asset and operating lease liabilities$80,116  $39,470

  • GlobeNewswire

    Exactus, Inc. Reports First Quarter 2020 Financial Results

    Exactus, Inc. (EXDI) (the “Company”) a leading supplier of hemp-derived ingredients (CBD/CBG) and feminized hemp genetics, today reported financial results for the first quarter 2020. During the first quarter of 2020, Exactus is pleased it has reported record revenue as its investment into sales and marketing has begun to generate revenue and scale. The Company has significantly cut its monthly cash burn and has shifted its focus to rapidly generate revenue through bulk specialty ingredient sales.